Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B

Thermo Fisher Scientific to Acquire QIAGEN for ~$11.5B

Shots:

  • Thermo Fisher to acquire QIAGEN in an all-cash transaction for $43.3/ share, making a total deal value ~$11.5B with a premium of 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on Mar 02, 2020. The transaction is expected to be completed in H1’21
  • The focus of the acquisition is to expand Thermo Fisher’s specialty diagnostics portfolio with attractive molecular diagnostics capabilities, complements its life sciences offering with innovative sample preparation, assay and bioinformatics technologies and expand its customer access
  • The acquisition provides Thermo Fisher an opportunity to leverage its capabilities and R&D expertise to accelerate innovation, addressing the emerging healthcare needs

Click here ­to­ read full press release/ article | Ref: Qiagen | Image: Wikipedia